Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel + S-1 for locally advanced or metastatic pancreatic cancer (GAS)
ChiCTR2300068818Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and tegafur in pancreatic cancer (PC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate (ORR). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
gemcitabinepaclitaxeltegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300068818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068818.